Objective: It is estimated that as many as 38% of cancer patients suffer from depression, which may have distal impacts on cancer care, including clinical outcomes, health care utilization, and cost of care. The purpose of this study was to determine the impact of depression on overall healthcare utilization among patients with cancer.
Introduction
Depression is a common psychiatric condition affecting patients diagnosed with all types of cancer. A recent meta-analysis indicated that the pooled prevalence of depression ranges from 8 to 24% [1] , while other estimates suggest the prevalence may be as high as 38% [2] . In contrast, the 1-year prevalence of depression in the general population is about 7% [3, 4] , and the prevalence among primary care patients ranges from 14 to 31% [5] .
Depression itself is a serious medical condition with distal impacts on cancer care. Elevated symptoms of depression have been associated with a reduced 5-year chance of survival among individuals with cancer, after controlling for histopathological grade, number of positive lymph nodes, tumor size, type of operation received, chemotherapy and/or endocrine therapy, estrogen-receptor status, and age [6] . Increased mortality risk has been demonstrated in patients with elevated depressive symptoms [7] , independent of disease stage, disease type (e.g. breast cancer, lung cancer, brain cancer), or whether depression was assessed prior to or after the cancer diagnosis.
While the direct costs of treating depression are substantial [8] , indirect costs are also likely increased via increased healthcare utilization. Depressed elderly HMO patients have 38% more outpatient healthcare visits and 61% higher healthcare charges relative to non-depressed patients [9] . Depressed primary care patients have a greater number of annual healthcare visits, specialist referrals, and radiologic tests relative to non-depressed patients [10] . Similarly, depressed primary care patients aged 65 years or older have significantly more annual outpatient healthcare visits, laboratory tests, radiologic procedures and scans, and consultations with medical, surgical, and other specialists relative to non-depressed patients [11] . Finally, depression has been associated with increased risks of inpatient hospitalizations, length of hospital stays, and 30-day hospital readmissions [12] , although the preponderance of these studies focused on general medical patients rather than cancer patients specifically. One study that included patients with prostate, breast, lung, or colon cancer found that those with depression were at increased risk for emergency department visit and inpatient hospital admission relative to those without depression [13] .
This study sought to determine whether depression in cancer patients was associated with increased healthcare utilization by examining unique elements of healthcare use such as emergency department visits, hospitalization rates, and 30-day rehospitalization rates in depressed vs non-depressed patients with cancer. It was expected that patients with cancer and depression would have: (a) greater overall healthcare service utilization, (b) higher risk for emergency department visits, (c) higher risk for hospitalizations, and (d) among patients with a hospitalization, higher risk of 30-day rehospitalization.
Methods

Participants
The sample consisted of 5055 outpatients with an ICD-9 diagnosis of any cancer occurring between January 1 and March 31, 2011, who were seen from January 1, 2011 to December 31, 2011 , at the University of California San Diego (UC San Diego) Healthcare System in San Diego, California. Patients diagnosed between January and March were selected to account for the expected decrease in healthcare visits that would occur in patients diagnosed in the latter portion of the year. Data were obtained from electronic medical records and included ICD-9 diagnostic codes, encounter history, demographic information, and hospital and emergency department admissions information. To allow for an evaluation of annual healthcare utilization, subjects that died in 2011 were excluded. The study was approved by the UC San Diego Institutional Review Board.
Measures
Demographic information
Extracted demographics included patient age, gender, and race/ethnicity.
Health care utilization
Health care utilization was defined as the number of visits with non-mental health healthcare providers in the UC San Diego healthcare system in the year 2011. The following contact types where extracted and analyzed: Office visit; external hospital admission; hospital; allied health/nurse visit; physical therapy; occupational therapy; speech therapy; respiratory therapy; clinic lab; pharmacy services; clinic procedure; hospital encounter; inpatient surgery; interventional radiology; procedure visit; consultation; nurse procedure visit; surgery; anesthesia; anesthesia event; face-to-face consultations, telephone contacts, diagnostics and minor surgery, and contacts for prescribing medication. The total number of contacts was calculated as the sum of these categories. In addition, the following were separately extracted from medical records (a) whether or not patients made any emergency department visits, and (b) whether or not patient experienced any inpatient hospitalizations.
Depression diagnosis
Depressive illness was extracted from patients' medical records. Consistent with prior studies [10, 11, 14, 15] , patients with an ICD-9 diagnostic code of 296.2, 296.3, 300.4, or 311 in the year 2011 were coded as 'depressed'.
Medical comorbidity
For each patient, the Deyo et al. [16] version of Charlson Comorbidity Index score [17] was computed. The Deyo disease weights account for advances in disease management since the original scale's inception, and represent a weighted index that accounts for the number and the seriousness of comorbid disease. It is a valid predictor of physician visits, prescription drug use, hospitalization, cost, and mortality [17] [18] [19] [20] . It was of particular interest to evaluate the added effect of metastatic tumors to overall healthcare utilization. As such, the value for metastatic cancer was removed from the overall Charlson score and included as a separate covariate.
Insurance
Each participant received a code for their insurance carrier. Three forms of insurance were coded: private insurance carrier, Medicare or Medi-Cal (California's Medicaid program), and Self-pay. For the analysis, two dummy codes were created with 'private insurance' as the reference category.
Statistical analyses
First, the mean number of visits in 2011 for patients with depression vs no depression was first analyzed using t-tests. The standardized mean difference in total visits was computed via the Cohen's d effect size. In addition, because total visits demonstrated significant positive skewness, the median number of visits for each year were compared via Mann-Whitney U tests. For each of these analyses, a probabilistic index was computed [21] , which is a clinically relevant effect size indicating the probability that a randomly selected patient with depression had a greater number of annual healthcare visits compared to a randomly selected nondepressed patient.
Next, multivariate analyses were conducted. Negative binomial regression was used to evaluate the adjusted incidence rate ratio (aRR) of depression on overall healthcare utilization, adjusted for age, gender, race/ethnicity, insurance status, medical comorbidity, months with cancer, and metastasis. Negative binomial regression was used because of over-dispersion, the count nature of the outcome data, and better goodness of fit statistics compared to Poisson regression.
Emergency Department, overnight hospitalization, and 30-day hospital readmission outcomes were analyzed using logistic regression analyses. An analyses using depression as the sole predictor of these outcomes was first conducted, followed multivariate logistic regression analyses which controlled for the same set of demographic and health covariates described above. Multivariate Analysis of Covariance (ANCOVA) was used to compare mean lengths of stay in the hospital for depressed vs nondepressed patients, adjusting for the same covariates as previously described. For all analyses, to control for multiple comparisons, significance levels were adjusted using Bonferroni correction (i.e. α/5 = 0.01).
Following our initial analyses, we performed secondary analyses to examine the relations between depression and healthcare utilization by cancer site. In these analyses, we originally considered replicating our original analyses by including the same set of covariates in predicting healthcare use. However, because our overall sample consisted of individuals with a broad variety of cancers, many of which had relatively small sample sizes (i.e. <150 patients), we were concerned that low events per variable (EPV) would produce inaccurate or imprecise regression coefficients [22] . Therefore, to minimize risk associated with low EPV, and to maintain consistency in these analyses across cancer site, our follow-up analyses included depression as the sole predictor of outcomes.
Results
Sample characteristics
Characteristics of the sample can be found in Table 1 . Statistically significant differences were found whereby depressed patients were significantly younger, more likely to be female, and had significantly greater medical comorbidity scores. Similar proportions of each type of cancer were found, except that depressed patients appeared more likely to have breast cancer and less likely to have genitourinary cancer.
Total healthcare utilization
Results presented in the text below are from the univariate analyses, whereas results presented in Tables 2 and 3 are for multivariate analyses. Results of our secondary analyses, stratified by cancer site, are presented in Supplementary Tables 1 and 2 . The mean number of visits for patients with depression (n = 561) and without depression (n = 4494), was 29.3 ± 27.7 and 14.7 ± 19.2 (t = 16.00, df = 5053, p < 0.001), respectively, with a Cohen's d effect size of 0.72. Results of the nonparametric Mann-Whitney U test confirmed that patients with depression made greater use of the healthcare system (median = 21, IQR = 11-39) than non-depressed patients (median = 8, IQR = 3-19) (U = 1 829 080, Z = 17.46, p < 0.001). The probabilistic index P(X > Y) was 0.725, indicating a 72.5% probability that a randomly selected patient with depression had greater healthcare utilization than a randomly selected non-depressed patient.
Results of the multivariate negative binomial regression analysis are presented in Table 2 . Patients with depression made 76% more healthcare visits (estimated mean ± SE = 24.42 ± 1.07) relative to those without depression (estimated mean ± SE = 13.88 ± 0.21) (P < 0.05), with a Cohen's d [23] effect size of 0.67.
Risk for emergency department visit, hospitalization, and 30-day rehospitalization
A total of 675 patients (13.4%) had at least 1 emergency department visit over the course of the year. Of the depressed patients, 159 (28.3%) visited an emergency department, compared to 516 patients without depression (11.5%), and patients with depression were significantly more likely to visit the emergency department (Wald = 113.34, df = 1, p < 0.001; OR = 3.05, 95% CI = 2.48-3.74).
A total of 1238 patients (24.5%) had at least 1 hospitalization. A total of 222 depressed patients (39.6%) were hospitalized, compared to 1016 non-depressed patients (22.6%). Patients with depression were significantly more likely to be hospitalized (Wald = 74.68, df = 1, p < 0.001; OR = 2.24, 95% CI = 1.87-2.69). Examination of the mean length of stay indicated the estimated mean ± SE for depressed patients (6.1 ± 0.4) was significantly longer than non-depressed patients (4.7 ± 0.2) (F = 8.02, df = 1,1222, p = 0.005), but of small magnitude (Cohen's d = 0.11).
Of the 1238 patients with a hospital admission, 357 (28.8%) had a readmission within 30 days of discharge. Of the 222 depressed patients with a hospital admission, 98 (44.1%) experienced a 30-day readmission, compared to 259 of the non-depressed patients (25.5%). Patients with depression were significantly more likely than nondepressed patients to be re-hospitalized (Wald = 29.89, df = 1, p < 0.001; OR = 2.31, 95% CI = 1.71-3.12). Results of the multivariate analysis are presented in Table 3 .
Discussion
The primary finding of this study was that depression is associated with increased healthcare utilization in patients diagnosed with cancer. Specifically, after controlling for demographics, insurance type, medical comorbidity, time with cancer, and metastatic status, depressed patients had a mean of nearly 12 more annual visits to health providers. Further, because mental health visits were excluded from these analyses, this increase in utilization is not because of visits to mental health providers. While these results are consistent with other studies [10, 11] , the current study provides additional contributions. First, this study examined the role of depression on discreet elements of healthcare utilization such as increased risk for emergency department visits, risk for hospitalizations, hospital lengths of stay, and risk for 30-day rehospitalizations, all of which are of interest for clinical care, quality, and economic outcomes. Notable among these findings was that depressed cancer patients were 2.5 times more likely to visit an ED, 80% more likely to experience a hospitalization, and twice as likely to have a 30-day hospital readmission. Second, this study focuses on more than 5000 cancer patients seen throughout an entire healthcare system, which increases generalizability to the general population of cancer patients.
In terms of the magnitude of the difference in healthcare utilization between depressed and non-depressed patients, these results are comparable to, and in many cases larger, than those found in both community-dwelling patients and patients with chronic medical conditions, including cancer. Specifically, our study showed that depressed cancer patients were at 147% increased risk (RR = 2.47) for ED visit, 75% increased risk (RR = 1.75) for hospitalization, and 73% increased risk (RR = 1.73) for re-hospitalization relative to non-depressed cancer patients. By way of comparison, Himelhoch [13] found that depression was associated with a 29%-97% increased risk for ED visit in patients with depression and comorbid chronic medical condition, with the highest risk found in patients with prostate and breast cancers (97% and 93%, respectively). Further, our relative risk for depression was also higher than that found for patients with coronary heart disease (RR = 1.56), diabetes (RR = 1.81), congestive heart failure (RR = 1.29), and hypertension (RR = 1.82).
As to risk for hospitalization, our study found that our relative risk was well within the range of risk for chronic diseases reported in Himelhoch's study, including diabetes (94% increased risk), coronary artery disease (60% increased risk), and congestive heart failure (29% increased risk). Similarly, Prina [12] conducted a systematic review and meta-analysis of the relations between depression and risk for hospitalization in community-dwelling adults. Those results showed that depressed patients were at 36% increased risk (pooled RR = 1.36) for hospitalization relative to non-depressed patients. Similarly, both Wong [24] and Prina [25] found that depressed, community-dwelling adults were at significant risk for re-hospitalization relative to non-depressed patients (RR = 1.5 and 1.3, respectively). In sum, results of our study are very similar to those presented elsewhere, with depressed cancer patients being at comparable risk for medical service use to that of patients with chronic diseases, while being at greater risk compared to community-dwelling adults.
While the emphasis of this study was not on healthcare costs, these findings have potentially important implications for understanding added costs associated with depression. Estimates show that the median charge for the 10 most common reasons for ED visits is $1233 [26] . For hospital stays the mean 2012 cost has been estimated to be $10 400 [27] . For 30-day hospital readmissions for common medical conditions, the mean 2009 cost has been estimated to range from $11 200 to $13 000 [28] . Given the cost of ED admissions and hospitalizations, and the potential for increased use of these medical services in depressed cancer patients, future studies should examine actual costs associated with depression in this population while also focusing on quality and outcome measures.
The association between depression and increased service utilization may be because of high rates of somatization, symptom amplification, and heightened awareness of bodily sensation among depressed patients [29] . Relative to non-depressed patients, those with depression are 3-4 times more likely to complain of nonspecific symptoms such as fatigue, dizziness, headache, abdominal pain, and back pain [11] . While cancer and its treatments may be associated with an increase in these symptoms, these reports suggest that depressed cancer patients may report more frequent and/or more intense experiences of these non-specific symptoms, ultimately prompting more healthcare utilization.
Depression is a treatable condition. Meta analyses have demonstrated that psychological [30, 31] and pharmacologic [32] interventions are efficacious for reducing depressive symptoms, even among cancer patients [33, 34] . Reductions in health-care utilization because of management of depressive symptoms have been demonstrated previously in other populations with mixed results [35] [36] [37] . These studies, however, focused on primary care patients and their generalizability to specific medical conditions, such as cancer, is unknown. Follow-up studies are needed to examine whether treatment-related reductions in depression in cancer patients are associated with reduced healthcare utilization and costs, while improving care quality, quality of life, and health related outcomes.
This study had several strengths, including a large sample size, use of electronic medical records rather than self-report to determine overall healthcare use, and a focus on discreet service areas such as emergency department visits, hospitalizations, and 30-day rehospitalizations, which are also the focus of quality standards. Despite this, some limitations should be considered. For example, this retrospective study used ICD-9 chart diagnoses to assign depression status, and it is unclear what criteria providers used to determine the diagnosis. Given that depression is often underdiagnosed in medical patients [38] , it is likely that the number of patients with depression in this study is an underrepresentation of the true prevalence. Because patients classified in this study as non-depressed had significantly fewer visits as a whole, this potential underdiagnosis of depression may mean that the differences in healthcare utilization are smaller than reported. However, a prevalence of 11% for depression was found, consistent with that found in other studies [39] , Even so, future prospective studies will need to confirm these results using clinical interview and/or validated depression scales to more systematically determine depression status and severity, respectively.
A second limitation is that because this was a retrospective analysis of administrative data, we were unable to determine healthcare visits outside the UC San Diego Health system. Therefore, it is difficult to know how balanced the depressed and non-depressed groups are on this issue. For example, it is possible that depressed and high utilizing patients are more readily referred within the UC San Diego Health system as opposed to the community. As such, future studies should evaluate healthcare utilization encompassing multiple healthcare systems, or more readily account for visits to healthcare providers outside patients' primary systems.
Third, we did not have information on reasons for ED visit or hospitalization, and this should be evaluated in future studies to determine if depressed vs non-depressed cancer patients differ in their reasons for these visits. It is also unclear what proportion of the depressed patients in this study received any treatment for depression, and whether this treatment had any impact (increased for decreased) on non-mental health healthcare utilization. Future studies will want to examine the role of psychiatric or psychological treatments on depression, health outcomes, and healthcare utilization.
Another limitation was the lack of information on cancer stage and grade, which were not available in the clinical database from which data was extracted. Further, information on current cancer treatments was not available via the administrative database. To compensate, metastatic status was used to assess the contribution of cancer severity on overall healthcare utilization, which substitutes as a fairly good proxy. Indeed, metastasis was associated with greater healthcare utilization, greater risk for an ED visit, and higher risk for hospitalization and 30-day rehospitalization. Yet, it remains possible that patients with stage II or III tumors have more healthcare utilization than those with stage I tumors. Similarly, those receiving chemotherapy may also have greater prevalence of depression and/or higher healthcare utilization, including higher risk for re-hospitalization, than patients not receiving chemotherapy. Therefore, future prospective studies should systematically evaluate cancer stage and grade as predictors of healthcare utilization, as well as partial out the effects of current cancer treatment. Consistent with previous research, the Charlson index was significantly associated with increased service use in our study. However, the Charlson index codes for more serious medical conditions and may not account for other medical conditions that could impact overall service utilization.
Finally, we did not control for healthcare utilization prior to the year in which depression diagnosis appears in our administrative database. It is possible that baseline high utilizers of healthcare continue to use healthcare at high rates, and that depressive status does not impact these individuals to use increased health services. It is also possible that high service users ultimately go on to have higher rates of depression, which in turn could create a situation of 'confounding by exposure.' It is difficult to know the impact that previous year's healthcare use would have on the overall effect presented here, as the vast majority of studies we examined did not control for prior year healthcare use, or its impact on depression diagnosis [9] [10] [11] 13, 24, 25, [40] [41] [42] , and rarely do these studies differentiate if depression was incident or prevalent. Yet, while our approach of evaluating the role of depression on healthcare use was similar to prior studies, it is important that future studies consider and possibly tease out the important role of prior healthcare use on incident depression diagnosis as well as current year healthcare use.
In conclusion, these results suggest depression is associated significant increases in annual healthcare visits as well as greater risk of experiencing an ED visit, hospitalization, and 30-day rehospitalization. Among patients who were hospitalized, depressed patients had stays that were 30% longer than non-depressed patients. Depression is a risk indicator with potential to drive healthcare outcomes and costs, and improved recognition and treatment for depression in cancer patients could have a major impact on reducing overall healthcare utilization and costs, while improving quality of care and patient outcomes.
